Inotek Pharmaceuticals Corporation Appoints Claudine Prowse, Ph.D. as Vice President, Strategy and Investor Relations Officer
|View printer-friendly version|
Lexington, MA — July 20, 2015 — Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the appointment of Claudine Prowse, Ph.D., as Vice President, Strategy and Investor Relations. Dr. Prowse's responsibilities will include defining corporate strategy to expand business opportunities, corporate communications and investor relations, and interfacing with key external business and investor constituents. She will report directly to David P. Southwell, President and Chief Executive Officer, and serve as a member of the Inotek management team.
"We are delighted to welcome Claudine to Inotek during this important time for our company" said David P. Southwell, President and Chief Executive Officer. "Claudine is a respected biotechnology executive with a strategic mindset and keen sense of the role that science, innovation, and communication play in creating value. I anticipate that her strong blend of scientific understanding and accomplished history working with the financial community will be a significant asset as we work with Inotek's stakeholders."
Dr. Prowse has more than 15 years of experience in the biotechnology industry spanning small, mid and large cap biotech companies. Her prior roles include Vice President, Investor Relations at Biogen (NASDAQ: BIIB); Vice President, Investor Relations at Human Genome Sciences; Vice President and MEDACorp Product Manager, Leerink Swann; and Executive Director, Corporate Development at Isis Pharmaceuticals (NASDAQ: ISIS). She holds a B.S. in Biomedical Engineering from the University of California, San Diego (UCSD) School of Engineering and a Ph.D. in Biomedical Sciences from the UCSD School of Medicine.
"Inotek is at a key inflection point as we prepare to commence the Phase 3 development program for Trabodenoson," commented Dr. Prowse. "The Company has a highly collaborative culture based on a team of executives that have worked together in the past, and a track record of multiple NDA approvals followed by successful launches. I am very excited to join the Inotek team to help formulate and execute the long-term vision for the Company."
About Inotek Pharmaceuticals Corporation
Inotek Pharmaceuticals is focused on translating the science of the eye into novel therapies that improve the quality of life for patients with diseases that affect vision. Our groundbreaking innovation in adenosine science has yielded a new approach to glaucoma. Trabodenoson is being developed to address both the control of pressure in the eye, as well as the retinal damage that ultimately leads to vision loss. We are committed to achieving this with a much-improved side effect profile relative to existing therapies. Our product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination of trabodenoson with latanoprost given once-daily. Additionally, we are evaluating the potential for trabodenoson to directly target optic neuropathies.
This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these statements. These statements often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Claudine Prowse, Ph.D.
Vice President, Strategy and Investor Relations Officer